Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752728 | 1.00 | PIK3CA (0.62) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL856320 | 0.88 | PIK3CA (0.49) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3749745 | 0.88 | PIK3CA (0.49) | PIK3CAPRKDCMTORRIPK1GPR142 | |
| SCHEMBL2724334 | 0.86 | PIK3CA (0.47) | PIK3CAPRKDCCREBBPMTORRIPK1 | |
| SCHEMBL856145 | 0.85 | NR1H2 (0.48) | PIK3CAPRKDCCREBBPNR1H2RIPK1 | |
| SCHEMBL9288018 | 0.85 | PIK3CA (0.51) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3765369 | 0.84 | PIK3CA (0.45) | PIK3CAPRKDCCREBBPNR1H2RIPK1 | |
| SCHEMBL856311 | 0.84 | PIK3CA (0.48) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3754730 | 0.84 | PIK3CA (0.67) | PIK3CAPRKDCCREBBPMTORGPR142 | |
| SCHEMBL3277263 | 0.83 | PIK3CA (0.60) | PIK3CACREBBPRIPK1GPR142USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |